---
document_datetime: 2025-03-24 10:43:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vimkunya-epar-all-authorised-presentations_en.pdf
document_name: vimkunya-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7139072
conversion_datetime: 2025-12-22 12:19:07.882499
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   |     | Pharmaceutical Form      | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size            |
|------------------|-------------------|-----|--------------------------|---------------------------|----------------------------|---------------------------|----------------------|
| EU/1/25/1916/001 | Vimkunya          | --¹ | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.8 ml                    | 1 pre-filled syringe |

--¹

One dose (0.8 ml) contains:

40 µg chikungunya virus (CHIKV) virus-like particles *,** (VLP) adsorbed on aluminium hydroxide, hydrated (approximately 300 micrograms Al 3+  per 0.8 ml dose)..

* Produced in human embryonic kidney cells by recombinant DNA technology.

** Derived from CHIKV Senegal strain 37997 consisting of CHIKV capsid protein (C) and envelope proteins E1 and E2.